PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
22307137-10	2012	CONCLUSIONS: The combination of veliparib with metronomic cyclophosphamide is well tolerated and shows promising activity in a subset of patients with BRCA mutations.	Cyclophosphamide	58-74	BRCA1 DNA repair associated	Homo sapiens	151-155